MarketPulse

type 2 inflammation

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
BenzingaBenzinga··Vandana Singh

FDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis

FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

European Regulators Approve GSK's Biannual Asthma Drug Targeting Type 2 Inflammation

European regulators approve GSK's Exdensur, a biannual asthma injection targeting type 2 inflammation. The drug also treats chronic rhinosinusitis with nasal polyps, showing significant exacerbation reductions in trials.
GSKPhase 3 trialssevere asthma